Atea Pharmaceuticals announced six upcoming presentations at the 36th International Conference on Antiviral Research, ICAR, which will take place March 13-17, 2023 in Lyon, France. Presentation details are as follows: Title: The Combination of Bemnifosbuvir and Ruzasvir, the HCV NS5B and NS5A Inhibitors, Demonstrates Potent In Vitro Synergistic Antiviral Activity and In Vivo Preclinical Safety Without Adverse Interactions. Title: Low Risk of Drug-Drug Interactions for Bemnifosbuvir Based Upon In Vitro Metabolism and Transporter Interaction Studies. Title: Pharmacokinetics and Metabolism of [14C]-Bemnifosbuvir in Healthy Male Participants. Title: Bemnifosbuvir a Potent Inhibitor of SARS-CoV-2 Variants of Concern, and a Promising Oral Antiviral with a High Resistance Barrier for Treatment of COVID-19 and other Coronaviruses Infections. Title: AT-752 Targets Multiple Sites and Activities on the Dengue Virus Replication Enzyme NS5. Title: Five Cellular Enzymes in the Activation Pathway of Bemnifosbuvir, a Drug-Candidate Against SARS-CoV-2 Infections.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVIR:
- New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
- Atea Pharmaceuticals reports Q4 EPS (41c), consensus (45c)
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Atea Pharmaceuticals presents drug interaction profile of bemnifosbuvir
- Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023